Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Role of the xenobiotic-activated pregnane X receptor in type 1 and type 2 diabetes in male mice.

Biochemical pharmacology·2025

Same author

Estimated Glomerular Filtration Rate and Incident Prediabetes Risk in Normoglycemic Adults With Parental Type 2 Diabetes.

Journal of the Endocrine Society·2025

Same author

Pathobiology of Prediabetes: Understanding and Interrupting Progressive Dysglycemia and Associated Complications.

Diabetes·2025

Same author

Impact of Parental or First-Degree Family History of Diabetes on Diabetes Incidence and Progression During Long-term Follow-up in the Diabetes Prevention Program Outcomes Study.

Diabetes care·2025

Same author

Selective association of plasma sphingolipid species with insulin sensitivity and secretion in normoglycemic Black and White American adults.

Experimental biology and medicine (Maywood, N.J.)·2025

Same author

Plasma Sphingolipids in Relation to Glycemia and Glucose Tolerance in People Without Diabetes.

The Journal of clinical endocrinology and metabolism·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Prediabetes as a therapeutic target.

Omid Rad Pour¹, Samuel Dagogo-Jack

¹Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Clinical Chemistry

|November 11, 2010

Summary

This summary is machine-generated.

Prediabetes, characterized by impaired glucose levels, affects millions and increases the risk of type 2 diabetes and cardiovascular disease. Lifestyle changes and medications can prevent diabetes progression and reduce cardiometabolic risks.

Related Experiment Videos

Last Updated: Jun 6, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Area of Science:

Endocrinology
Metabolic Diseases
Cardiovascular Health

Background:

Prediabetes encompasses impaired glucose tolerance (IGT) and impaired fasting glucose (IFG).
Individuals with prediabetes face a heightened risk of developing type 2 diabetes within a decade.
There is an elevated risk of cardiovascular disease and mortality associated with prediabetes, even preceding diabetes diagnosis.

Purpose of the Study:

To review the epidemiology, pathophysiology, and clinical implications of prediabetes.
To present the rationale, goals, and intervention strategies for managing prediabetes.
To emphasize evidence from randomized controlled trials regarding prediabetes interventions.

Main Methods:

Review of epidemiological data on prediabetes prevalence.
Analysis of pathophysiological mechanisms underlying glucose intolerance.
Evaluation of clinical trial data on therapeutic interventions for prediabetes.

Main Results:

Approximately 57 million Americans have prediabetes, posing significant cardiometabolic risks.
Lifestyle modifications (diet, exercise) and medications are effective in preventing diabetes in prediabetic individuals.
Lifestyle interventions show promise in reducing cardiovascular disease risk markers, though clinical event data are limited.

Conclusions:

Prediabetes is a prevalent condition with serious cardiometabolic consequences.
Interventions, particularly lifestyle modifications, are crucial for preventing diabetes and mitigating cardiovascular risks.
Further research is needed to clarify the impact of interventions on clinical cardiovascular events.